Release date: July 10, 2025
Expiration date: July 9, 2027
Estimated Time of Completion: 1 hour and 45 minutes
Session Agenda
Infectious complications from biologic therapy
Cassandra Calabrese, DO
Immune related adverse events from checkpoint inhibitor therapy: targeted therapies
Noha Abdelwahab Hassan, MD, PhD
Moneyball Rheumatology - Making the most out of our time and data for better care of our patients
Jack Cush, MD
Description
Biologic Therapies Summit XI Webcast Series, repurposed from the 2025 Biologic Therapies Summit XI, is designed for healthcare professionals seeking to deepen their understanding of cutting-edge treatments for immune-mediated inflammatory diseases.
Learning Objectives
- Investigate and differentiate between infectious complications from biologic therapies and immune-related adverse events associated with checkpoint inhibitor therapies, while formulating effective prevention and management strategies.
Target Audience
The online series is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.
Accreditation
In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians / American Medical Association (AMA)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
Nurses / American Nurses Credentialing Center (ANCC)
Cleveland Clinic Center for Continuing Education designates this internet enduring activity for a maximum of 1.75 ANCC contact hours.
Physician Assistants / American Academy of PAs (AAPA)
Cleveland Clinic Center for Continuing Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Certificate of Participation
A certificate of participation will be provided to other health care professionals for requesting credits in accordance with their professional boards and/or associations.
Activity Director and Faculty
Activity Directors
Leonard H. Calabrese, DO
R.J. Fasenmyer Chair of Clinical Immunology
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH
Cassandra Calabrese, DO
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH
M. Elaine Husni, MD, MPH
Director, Arthritis and Musculoskeletal Treatment Center
Vice Chair, Rheumatology
Department of Rheumatic & Immunologic Diseases
Medical Specialty Institute
Cleveland Clinic
Cleveland, OH
Additional Planners
Debra Kangisser, PA-C
Elizabeth (Betsy) Kirchner, DNP
Faculty
Jack Cush, MD
Executive Editor, RheumNow.com
Noha Abdelwahab Hassan, MD, PhD
Assistant Professor, Department of Section of Rheumatology and Clinical Immunology
Department of General Internal Medicine
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
Faculty Disclosure
In accordance with the Standards for Integrity and Independence issued by the Accreditation Council for Continuing Medical Education (ACCME), Cleveland Clinic Center for Continuing Education mitigates all relevant conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated they have no relationship which, in the context of his/her presentation(s), could be perceived as a potential conflict of interest
| Cassandra Calabrese, DO |
Astra Zeneca
Sanofi-Regeneron |
Consulting
Teaching and Speaking |
| Lilly |
Consulting (Ended: 12/01/2023) |
| Pfizer |
Consulting (Ended: 07/01/2023) |
| Leonard Calabrese, DO |
| Astra Zeneca |
Teaching and Speaking |
| Sanofi Aventis |
Consulting |
| Genentech/Roche |
Consulting
Advisor or review panel participant
Teaching and Speaking |
| Novartis |
Consulting |
UCB
Janssen |
Consulting
Teaching and Speaking |
| Abbvie Pharmaceuticals |
Consulting |
| J. Jack Cush, MD |
Bristol-Myers Squibb Co.
Novartis
UCB
Abbvie Pharmaceuticals
Sanofi |
Consulting
Advisor or review panel participant |
| M. Elaine Husni, MD |
Lilly
Amgen
Bristol-Myers Squibb Co.
Janssen
AbbVie Pharmaceuticals |
Consulting
Advisor or review panel participant |
| Novartis Pharmaceuticals |
Consulting
Advisor or review panel participant
Teaching and Speaking |
| Pfizer, Inc. |
Advisor or review panel participant |
| UCB, Inc. |
Consulting |
| Regeneron |
Consulting (Ended: 01/01/2024)
Advisor or review panel participant (Ended: 01/01/2024) |
| National Psoriasis Foundation |
Other activities from which remuneration is received or expected
Research |
| Elizabeth Kirchner, DNP |
| Lilly |
Consulting (Ended: 06/29/2023) |
| Pfizer |
Consulting (Ended: 11/09/2023) |
| Boehringer Ingelheim |
Advisor or review panel participant (Ended: 09/08/2022) |
| UCB |
Advisor or review panel participant (Ended: 10/17/2022) |
| Horizon Pharma |
Advisor or review panel participant (Ended: 09/08/2022) |
| Janssen Pharmaceuticals, Inc. |
Consulting (Ended: 12/07/2023) |
| RhAPP |
Teaching and Speaking |
All other individuals have indicated no relationship which, in the context of their involvement, could be perceived as a potential conflict of interest.
Acknowledgment
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Genentech
Janssen Scientific Affairs, LLC
UCB, Inc.
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Department of Rheumatic & Immunologic Diseases, and Cleveland Clinic’s RJ Fasenmyer Center for Clinical Immunology.
